This case report highlights the potential for acute myocardial infarction presenting without typical chest pain during amivantamab therapy, emphasizing the need for careful monitoring of atypical symptoms and laboratory abnormalities in cardio-oncology.
May warrant monitoring for silent MI on amivantamab; leaves open causal link.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: